Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement

03-Nov-2014 - Switzerland

Bristol-Myers Squibb Company and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.

Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline. Bristol-Myers Squibb and Lonza have been collaborating since 2003 to produce commercial supplies of a biologics medicine marketed by Bristol-Myers Squibb worldwide. Currently, Lonza also produces clinical supplies of an investigational biologics medicine for Bristol-Myers Squibb.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances